




RealRate

PHARMACEUTICAL 2021

Oncosec Medical Inc
Rank 329 of 394

oncosec
IMMUNOTHERAPIES



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Oncosec Medical Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncosec Medical Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 4.6% points. The greatest weakness of Oncosec Medical Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 118% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	22,822
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,678
Liabilities, Non-Current	5,874
Other Assets	6,267
Other Compr. Net Income	-189
Other Expenses	-867
Other Liabilities	481
Other Net Income	288
Other Revenues	0
Property and Equipment	814
Research and Development	25,097
Selling, General and Administrative Expense	18,312

Output Variable	Value in 1000 USD
Assets	29,903
Liabilities	16,033
Expenses	42,542
Revenues	0
Stockholders Equity	13,870
Net Income	-42,253
Comprehensive Net Income	-42,348
BaseVar	44,477
ECR before LimitedLiability	-53%
Economic Capital Ratio	138%